Return to List
Study Summary
No.
DM02-385:
.......
Leukemia; CTRC(Translational Research)
......
Susan O'Brien
......
Leukemia
.
Study Summary Title
Study Summary
Number:
DM02-385
Study Title:
A Phase I Multicenter, Dose-Escalation Study of IDEC - 152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
Physician
New Patient Referral
Name:
Susan O'Brien
Patients Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:
Leukemia
Referring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:
713-792-7543
Contact us about clinical trials
.
General Information
Disease Group:
Leukemia
CTRC(Translational Research)
Supported By:
IDEC Pharmaceutical Corp.
Phase of Study:
Phase I
Return
Visit:
The following is a schedule of return visits for this protocol days 29, 36, 43 & 50; months 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, & 48 from completion of study drug.
Treatment
Agents:
idec-152
Home Care:
None needed
Treatment Loc:
outpatient
Estimated
Length of Stay
in Houston:
4 weeks
Description/
Intervention:
Unavailable
.
Study Objectives / Outcomes
Unavailable
.
Study Status Information
Study Activation / Registration Date:
11/15/2002
IRB Review and Approval Date:
10/31/2002
Study Type:
Therapeutic
Recruitment Status:
Closed
Projected Accrual:
70
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you.
Please Contact the
Referral Office
for more information.
Inclusion Criteria:
Signed, written IRB-approved informed consent.
.
Links
Registration Number:
Other Links:
.
Results
Return to Clinical Trials at M.D. Anderson Cancer Center
